Nonsteroidal anti-inflammatory drugs in perioperative period of cataract surgery
https://doi.org/10.51793/OS.2025.28.4.011
Abstract
Background. Medication support of cataract surgery is an integral part of it. The standard regimen of local therapy includes an antibiotic, a glucocorticosteroid, and a nonsteroidal anti-inflammatory drug. Each of the many nonsteroidal anti-inflammatory drugs has unique pharmacological properties, which determines the relevance of information on the choice of a drug from this group in the drug support of cataract surgery.
Objective. The purpose of this study is to form an up-to-date understanding of nonsteroidal anti-inflammatory drugs in the drug support of the perioperative period of cataract surgery. The study was conducted in the format of a narrative review. The variety of topical nonsteroidal anti-inflammatory drugs used in ophthalmology is represented by diclofenac, ketorolac, bromfenac, indomethacin, and nepafenac. Differences in the chemical structure of the drugs determine the features of their pharmacodynamics and pharmacokinetics. A significant amount of evidence has accumulated in the literature in the form of results of randomized studies with a control group and experimental works indicating positive anti-inflammatory properties of nonsteroidal anti-inflammatory drugs used in the perioperative period of cataract surgery.
Conclusion. The presented studies demonstrate that nepafenac exhibits significant pharmacodynamic properties for penetration into the anterior chamber of the eye, and also has an anti-inflammatory effect in the posterior segment of the eye against the background of local application, which determines the unique therapeutic potential of Apfecto. Apfecto is a cost-effective generic nepafenac produced with international quality standards.
About the Authors
I. A. Levashov
Multidisciplinary Medical Center of the Central Bank of the Russian Federation
Россия
Россия
Ilia A. Levashov - Cand. of Sci. (Med.), ophthalmologist of the Surgical Department, Multidisciplinary Medical Center of the Central Bank Of the Russian Federation.
66 Sevastopolsky Prospekt, Moscow, 117593
D. B. Gorodetskiy
N.I. Pirogov Russian National Research Medical University
Россия
Россия
Dmitriy B. Gorodetskiy - student of the Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation.
1 Ostrovityanova str., Moscow, 117997
References
1. Malyugin B. E., Shpak A. A., Morozova T. A. Pharmacologic support of modern cataract surgery. 27 p. (In Russ.)
2. Stein J. D. Serious adverse events after cataract surgery. Curr. Opin. Ophthalmol. 2012; 23 (3): 219-225.
3. Gaskin G. L., et al. Predictive Modeling of Risk Factors and Complications of Cataract Surgery. Eur. J. Ophthalmol. 2016; 26 (4): 328-337.
4. Nowak J. Z. Non-steroidal anti-inflammatory drugs (NSAIDs) in ophthalmology: pharmacological and clinical characteristics. Mil. Pharm. Med. 2012; 4: 33-50.
5. Hoffman R. S., et al. Cataract surgery and non-steroidal antiinflammatory drugs. J. Cataract Refract. Surg. 2016; 42 (9): 1368-1379.
6. Kim S. J., Flach A. J., Jampol L. M. Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Surv. Ophthalmol. 2010; 55 (2): 108-133.
7. Hirneiß C., et al. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. Graefe’s Arch. Clin. Exp. Ophthalmol. 2005; 243 (8): 768-773.
8. Srinivasan R., Madhavaranga. Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J. Cataract Refract. Surg. 2002; 28 (3): 517-520.
9. Malyugin B. E., Anisimova N. S., Sobolev N. P. Features of diaphragmatic iris function at femtosecond laser support of phacoemulsification against the background of application of various non-steroidal anti-inflammatory agents. Oftalmokhirurgiya. 2018; 1: 6-12. (In Russ.)
10. Kim S. J., et al. Topical Nonsteroidal Antiinflammatory Drugs and Cataract Surgery. Ophthalmology. 2015; 122 (11): 2159-2168.
11. Ioshin I. E., Tolchinskaya A. I., Ozderbaeva A. A. Features of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of macular retinal edema after phacoemulsification of age-related cataract. Rossiiskii oftalmologicheskii zhurnal. 2016; 9 (2): 77-82. (In Russ.)
12. Almeida D. R. P., et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J. Cataract Refract. Surg. 2012; 38 (9): 1537-1543.
13. Costagliola C., et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp. Eye Res. 2005; 81 (5): 610-615.
14. Lindstrom R., Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr. Med. Res. Opin. 2006; 22 (2): 397-404.
15. Gamache D. A., Graff G., Brady M. T. Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy. Inflammation. 2000; 24: 357-370.
16. Kapin M. A., et al. Inflammation-Mediated Retinal Edema in the Rabbit Is Inhibited by Topical Nepafenac. Inflammation. 2003; 27: 281-291.
17. Lane S. S., et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J. Cataract Refract. Surg. 2007; 1 (33): 53-58.
Review
For citations:
Levashov I.A., Gorodetskiy D.B. Nonsteroidal anti-inflammatory drugs in perioperative period of cataract surgery. Lechaschi Vrach. 2025;(4):76-79. (In Russ.) https://doi.org/10.51793/OS.2025.28.4.011
Views:
83
JATS XML
Email this article 
